checkAd

DGAP-News Formycon Publishes Half-Year Results for 2021

Nachrichtenquelle: EQS Group AG
21.09.2021, 07:30  |  104   |   |   

DGAP-News: Formycon AG / Key word(s): Half Year Report/Half Year Results
Formycon Publishes Half-Year Results for 2021

21.09.2021 / 07:30
The issuer is solely responsible for the content of this announcement.


 



Press Release // September 21, 2021

Formycon Publishes Half-Year Results for 2021

- Group turnover above H1 half-year level at Euro 20.3 million

- EBITDA of Euro -9.7 million and half-year results of Euro -10.2 million in line with plans

- Result due to investments in the non-partnered projects FYB206 and FYB207

- Significant progress in the biosimilar projects and the COVID-19 drug

Munich - Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) has today announced its financial results for the first half of 2021.

On the day of reporting, June 30, 2021, the Formycon Group's financial figures were as forecast. Turnover within the Group which, alongside the joint-stock company also includes two fully consolidated subsidiaries Formycon Project 201 GmbH and Formycon Project 203 GmbH, as well as the shareholding in FYB 202 GmbH & Co. KG which is not consolidated, stood at a total of Euro 20.3 million in the first six months of 2021 (H1/2020: Euro 16.5 million). For the full year of 2021, Formycon forecasts revenues above last year's level for the entire Group (2020: Euro 34.2 million).

During the company's current phase, the Formycon Group is focusing on research and development activities for its own and licensed biosimilar projects, as well as its own COVID-19 drug (FYB207). The current revenues also result from the development services for the out-licensed or partnered projects. Following the successful approval of these products, Formycon will also take a share of subsequent commercialization revenues.

The Group's earnings before interest, tax, depreciation and amortization (EBITDA) stood at Euro -9.7 million (H1/2020: Euro -0.9 million), the operating result (EBIT) and the consolidated net profit for the period were around Euro -10.2 million as of June 30, 2021, compared with Euro -1.4 million in the prior-year period.

Seite 1 von 4
Formycon Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de




Diskussion: Formycon AG - Informationssammelthread
Wertpapier



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

DGAP-News Formycon Publishes Half-Year Results for 2021 DGAP-News: Formycon AG / Key word(s): Half Year Report/Half Year Results Formycon Publishes Half-Year Results for 2021 21.09.2021 / 07:30 The issuer is solely responsible for the content of this announcement.   Press Release // September 21, 2021 …

Community

Nachrichten des Autors

Titel
Titel
Titel
Titel

Nachrichten zu den Werten

DatumTitel
04:44 UhrCannabis und Biotech: Canopy, Tilray, Sativa Wellness, Formycon – Die nächste Cannabis-Rakete finden!
inv3st.de | Unternehmensnachrichten
Anzeige
20.10.21Wasser: Memiontec, Formycon, Synlab – Handeln, bevor es zu spät ist!
inv3st.de | Unternehmensnachrichten
Anzeige
19.10.21DGAP-News: Formycon and SCG Cell Therapy Announce Collaboration and License Agreement for Formycon's COVID-19 Drug FYB207
EQS Group AG | Weitere Nachrichten
19.10.21DGAP-News: Formycon und SCG Cell Therapy geben Kooperations- und Lizenzvereinbarung für Formycons COVID-19-Medikament FYB207 bekannt
EQS Group AG | Weitere Nachrichten
18.10.21DGAP-Adhoc: Formycon schließt Kooperations- und Lizenzvereinbarung für COVID-19-Medikament FYB207 mit SCG Cell Therapy für asiatisch-pazifische Region ab
EQS Group AG | Ad-hocs
18.10.21DGAP-Adhoc: Formycon Concludes Collaboration and License Agreement with SCG Cell Therapy for its COVID-19 Drug FYB207 for the Asia Pacific Region
EQS Group AG | Ad-hocs
18.10.21Söllners Hot Stock Report: "Überraschung" JinkoSolar, Plug Power, Bitcoin, Amazon, Valneva, BioNTech, Tesla, VW, Varta, SDI
Der Aktionär TV | Marktberichte
18.10.21Söllners HSR: "Überraschung" Jinko, Plug, Bitcoin, Amazon, Valneva, BioNTech, Tesla, VW, Varta, SDI
Der Aktionär TV | Marktberichte
04.10.21Formycon: FDA hebt den Daumen – jetzt gilt es!
Sharedeals | Weitere Nachrichten
04.10.21Söllners HSR: Merck, BioNTech, Bitcoin, Tesla, BMW, VW, Samsung SDI, NovaVax
Der Aktionär TV | Marktberichte